Loading...

Akebia Therapeutics, Inc.

AKBANASDAQ
Healthcare
Biotechnology
$3.56
$-0.28(-7.29%)

Fundamental Analysis of Akebia Therapeutics, Inc. (AKBA)

Comprehensive financial metrics and ratios analysis
EPS (TTM)
$-0.21
P/E Ratio
-16.95
ROE
1.67%
Net Margin
-0.25%

Key Financial Metrices

Valuation Metrics

4 metrics
Market CapTotal market value of outstanding shares
$934.98M
Shares OutstandingTotal number of shares issued
$262.64M
Book Value/ShareNet worth per share
$0.10
Revenue/ShareAnnual revenue per share
$0.79

Profitability Metrics

6 metrics
EPS (TTM)Earnings per share trailing twelve months
$-0.21
Net MarginNet income as percentage of revenue
-24.51%
Operating MarginOperating income as percentage of revenue
-11.91%
ROEReturn on shareholders' equity
166.65%
ROAReturn on total assets
-14.61%
ROCEReturn on capital employed
-10.06%

Cash Flow Metrics

3 metrics
Free Cash Flow/ShareCash generated per share after capex
$-0.15
Cash/ShareCash and equivalents per share
$0.48
FCF YieldFree cash flow as percentage of market cap
-3.73%

Dividend Metrics

2 metrics
Dividend/ShareAnnual dividend payment per share
-
Dividend YieldAnnual dividend as percentage of stock price
-
Financial Ratios Analysis data is not available for AKBAFinancial Ratios Analysis details for AKBA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Sector Benchmarking data is not available for AKBASector Benchmarking details for AKBA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Akebia Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Akebia Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Akebia Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Akebia Therapeutics, Inc.

For Akebia Therapeutics, Inc., essential financial indicators include EPS -0.21, PE -16.95, and ROE 1.67. These key ratios reveal insights into Akebia Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Akebia Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Akebia Therapeutics, Inc.

Metrics like Net Margin -24.51% and ROA -14.61% shed light on how well Akebia Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Akebia Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Akebia Therapeutics, Inc.

Using ratios such as P/B Ratio 34.25 and PEG Ratio -0.56, investors can assess whether Akebia Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Akebia Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Akebia Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 2.20 and Cash Flow $-0.15, provide a snapshot of Akebia Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Akebia Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Akebia Therapeutics, Inc.

Investing in Akebia Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Akebia Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;